Quidel

News Release

Printer Friendly Version View printer-friendly version
<< Back
Quidel Announces Strategic Business Partnerships at ASBMR Conference; Specialty Products Group Expands Global Capabilities in Osteoporosis Products

SAN DIEGO--(BUSINESS WIRE)--Sept. 26, 2005--Quidel Corporation (Nasdaq:QDEL) today announced at the 27th Annual American Society of Bone and Mineral Research (ASBMR) conference in Nashville, TN, that its Specialty Products Group (SPG) has secured strategic co-marketing agreements with Cambrex Bio Science Walkersville, Inc., based in Walkersville, MD and Nordic Bioscience Diagnostics A/S, based in Herlev, Denmark. These partnerships will leverage Quidel's global capabilities to collaborate with osteoporosis research institutions for the development of new markers which may benefit osteoporosis and post-menopausal patients.

"With these strategic business partnerships, Quidel is poised to advance the development of markers in the field of bone health and osteoporosis," said Noah Nasser, general manager of the Specialty Products Group. "These alliances provide a gateway for Quidel to fuel and further expand its growth and development in the global bone health industry, by tapping into new, international markets and sales opportunities," he added.

Quidel's two-year partnership with Nordic Bioscience Diagnostics is a co-marketing and sales alliance for promoting both company's diagnostic bone assays into the Nordic and Baltic states, creating a unique diagnostic solution for analyzing bone turnover.

In return, Quidel will sell Nordic Bioscience Diagnostics' Serum CrossLaps(R) ELISA (CTX-I, an in vitro diagnostic kit for measuring bone resorption) in the U.S. market. The tests will be positioned as a package for measuring total bone turnover (both resorption and formation). This partnership with Nordic Bioscience Diagnostics enables Quidel to provide clinicians and researchers with an unprecedented opportunity to measure bone turnover and better understand the underlying nature of osteoporosis and related diseases.

"This alliance positions both companies to further strengthen market leadership and increase sales potential globally," said Dr. Dagmar Kasper, head of sales and marketing, Nordic Bioscience Diagnostics. "More importantly, it allows both partners to collaborate in helping to lower overall healthcare costs and improve the quality of healthcare today," she added.

The co-marketing agreement with Cambrex Bio Science Walkersville, Inc., enables Quidel's Metra(R) Helical Peptide assay to be combined with Cambrex's OsteoAssay(TM) Human Bone Plate, creating an integrated solution for measuring bone resorption.

"The combination of the Metra(R) Helical Peptide immunoassay and the OsteoAssay(TM) plate provides more consistent and reliable data than that obtained with either dentine discs or bovine bone slices," said Dr. Dale Greenwalt, Manager of BioAssay Development, Cambrex Bio Science.

About Quidel Corp.

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential point-of-care applications in the future. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com.

About Cambrex Bio Science Walkersville, Inc.

Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation (NYSE:CBM), is the leader in the technical development of cell systems, providing innovative solutions to facilitate and standardize research. In addition to cell systems, they are a convenient source of hundreds of normal primary derived cells, stem cells, separation systems and optimized cell culture media. All components in each system are manufactured under standardized procedures and are tested together and guaranteed to provide optimum performance.

About Nordic Bioscience Diagnostics

Based in Denmark, Nordic Bioscience is a special biotechnology company committed to the development of therapeutic compounds and diagnostic products for improving the management of patients suffering from diseases affecting bone and cartilage, such as osteoporosis, osteoarthritis and bone metastasis. The main business activities of Nordic Bioscience are focused on sales of existing diagnostic products, drug discovery, drug development and development of biochemical markers.

They have an extensive portfolio which includes several FDA cleared ELISA kits (including CrossLaps(R)) used in both pharmaceutical research and routine patient assessment of bone turnover and cartilage degradation. Nordic Bioscience Diagnostics has operated a U.S. based subsidiary since 2002 and is represented in over 40 countries through a network of distributorships and sales representatives. More than half of its employees are engaged in research and development. For more information, please visit www.nbdiagnostics.com.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration ("FDA"), intellectual property, product liability, environmental or other litigation, and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.

CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962

SOURCE: Quidel Corporation